• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kiniksa Pharmaceuticals International plc

    2/25/25 4:31:11 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email
    S-8 1 tm256599d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 25, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    Kiniksa Pharmaceuticals International, plc 

    (Exact name of registrant as specified in its charter)

     

    England and Wales   98-1795578
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)

     

    23 Old Bond Street, Floor 3

    London, W1S 4PZ

    England, United Kingdom

    (Address of Principal Executive Offices) (Zip Code)

     

    Kiniksa Pharmaceuticals International, plc 2018 Incentive Award Plan
    Kiniksa Pharmaceuticals International, plc 2018 Employee Share Purchase Plan
     

    (Full title of the plan)

     

    Kiniksa Pharmaceuticals Corp. 

    100 Hayden Avenue 

    Lexington, MA 02421 

    (Name and address for agent for service)

     

    (781) 431-9100 

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Paul M. Kinsella 

    Marko S. Zatylny 

    Ropes & Gray LLP 

    Prudential Tower 

    800 Boylston Street 

    Boston, Massachusetts 02199 

    (617) 951-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer x
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,900,642 Class A ordinary shares, nominal value $0.000273235 per share (“Class A ordinary shares”) of Kiniksa Pharmaceuticals International, plc (the “Registrant”) to be issued pursuant to the Registrant’s 2018 Incentive Award Plan (the “2018 Plan”) and an additional 90,000 Class A ordinary shares of the Registrant to be issued pursuant to the Registrant’s 2018 Employee Share Purchase Plan (the “2018 ESPP”). Registration Statements of the Registrant on Forms S-8 relating to the same employee benefit plans are effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF

     

    REGISTRATION STATEMENTS ON FORM S-8

     

    Except as set forth below, the contents of the Registration Statements on Form S-8 (Reg. Nos. 333-277480, 333-270226, 333-262971, 333-253514, 333-237589, 333-225196) filed with the Securities and Exchange Commission (the “Commission”) relating to the 2018 Plan and the 2018 ESPP, each as amended by a post-effective amendment number one, filed with the Commission on June 28, 2024, are incorporated by reference herein.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

        Incorporated by Reference
    Exhibit Number Exhibit Description Form File No. Exhibit Filing
    Date
    Filed
    Herewith
    4.1 Articles of Association of Kiniksa Pharmaceuticals International, plc 8-K12B 001-38492 3.1 6/28/2024  
                 
    4.2 Specimen Share Certificate evidencing the Class A Ordinary Shares 8-K12B 001-38492 4.1 6/28/2024  
                 
    5.1 Opinion of Ropes & Gray LLP, counsel to the Registrant         *
                 
    23.1 Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm         *
                 
    23.2 Consent of Ropes & Gray LLP (included in Exhibit 5.1)         *
                 
    24.1 Power of attorney (included on signature pages below)         *
                 
    99.1 2018 Incentive Award Plan and forms of award agreements thereunder 8-K12B 001-38492 10.4 6/28/2024  
                 
    99.2 2018 Incentive Award Plan; Subplan for UK Employees and forms of award agreements thereunder 8-K12B 001-38492 10.5 6/28/2024  
                 
    99.3 2018 Incentive Award Plan; Forms of option grant notice and option agreement for German participants, restricted share grant notice and restricted share agreement for German participants, and restricted share unit grant notice and restricted share unit agreement for German participants 8-K12B 001-38492 10.6 6/28/2024  
                 
    99.4 2018 Incentive Award Plan forms of option grant notice and option agreement for Swiss participants, restricted share grant notice and restricted share agreement for Swiss participants, and restricted share unit grant notice and restricted share unit agreement for Swiss participants 8-K12B 001-38492 10.7 6/282024  
                 
    99.5 Form of 2024 Performance Share Unit Grant Notice and 2024 Performance Share Unit Award Agreement 10-Q 001-38492 10.2 4/25/2024  
                 
    99.6 2018 Employee Share Purchase Plan 8-K12B 001-38492 10.8 6/28/2024  
                 
    107 Filing Fee Table.         *

     

     

    *Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on this 25th day of February 2025.

     

    KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC  
         
    By: /s/ Sanj K. Patel  
      Sanj K. Patel   
      Chief Executive Officer and Chairman of the Board  

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sanj K. Patel and Mark Ragosa, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE    TITLE    DATE 
             
    /s/ Sanj K. Patel   Chief Executive Officer and Chairman of the Board   February 25, 2025
    Sanj K. Patel   (principal executive officer)    
             
    /s/ Mark Ragosa   SVP, Chief Financial Officer   February 25, 2025
    Mark Ragosa   (principal financial officer)      
             
    /s/ Michael R. Megna   Group VP, Finance and Chief Accounting Officer   February 25, 2025
    Michael R. Megna   (principal accounting officer)    
           
    /s/ Felix J. Baker   Lead Independent Director   February 25, 2025
    Felix J. Baker        
             
    /s/ Stephen R. Biggar   Director   February 25, 2025
    Stephen R. Biggar        
             
    /s/ M. Cantey Boyd   Director   February 25, 2025
    M. Cantey Boyd    
             
    /s/ G. Bradley Cole   Director   February 25, 2025
    G. Bradley Cole        
             
    /s/ Richard S. Levy   Director   February 25, 2025
    Richard S. Levy        
         
    /s/ Thomas R. Malley   Director   February 25, 2025
    Thomas R. Malley        
         
    /s/ Tracey L. McCain   Director   February 25, 2025
    Tracey L. McCain        
         
    /s/ Kimberly J. Popovits   Director   February 25, 2025
    Kimberly J. Popovits        
         
    /s/ Barry D. Quart   Director   February 25, 2025
    Barry D. Quart        

     

     

     

     

    U.S. AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the duly authorized representative in the United States of the Registrant has signed this registration statement, on this 25th day of February 2025.

     

    KINIKSA PHARMACEUTICALS CORP.  
       
    By: /s/ Sanj K. Patel  
      Sanj K. Patel  
      Chief Executive Officer  

     

     

     

     

    Get the next $KNSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quart Barry D exercised 2,800 units of Class A Ordinary Share at a strike of $15.47 and sold $126,000 worth of Class A Ordinary Share (2,800 units at $45.00) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    2/12/26 4:34:44 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Ragosa Mark exercised 10,845 units of Class A Ordinary Share at a strike of $13.87 and sold $772,254 worth of Class A Ordinary Share (17,845 units at $43.28), decreasing direct ownership by 37% to 12,086 units (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    2/11/26 4:38:32 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Quart Barry D exercised 15,960 units of Class A Ordinary Share at a strike of $15.47 and sold $721,635 worth of Class A Ordinary Share (15,960 units at $45.22) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    2/4/26 6:24:23 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals Provides Corporate Update

    – ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update.

    1/12/26 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

    LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live webcast of Kiniksa's presentation will be accessible through the Investors section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and co

    1/7/26 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

    LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m. Eastern Time). A live webcast of Kiniksa's presentation will be accessible through the Investors section of the company's website at www.kiniksa.com. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring,

    11/12/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/13/24 7:34:05 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

    SCHEDULE 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    2/13/26 4:07:03 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Leadership Update

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    1/14/26 4:31:15 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

    1/12/26 5:22:53 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 202

    10/28/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

    LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and re

    10/23/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care